News — September 10, 2024 — The has issued updated guidelines, published in , . The journal is published in the Lippincott portfolio by .
"The complex etiology and variable severity of constipation symptoms mandate an individualized approach to evaluation and treatment," write senior author Ian M. Paquette, MD, of the University of Cincinnati, and his colleagues on the ASCRS Clinical Practice Guidelines Committee. After reviewing 134 English-language studies of adults published between January 1, 2014 and February 1, 2024, they developed 13 recommendations.
Strong recommendations
Each recommendation in the new guidelines is labeled "strong" or "conditional" using the GRADE system for evaluating the certainty of evidence in medical literature. The 6 strong recommendations are:
- A directed history and physical examination should be performed.
- The initial management of patients with symptomatic constipation involves dietary modifications and ensuring adequate fluid intake and fiber supplementation.
- Osmotic laxatives are an appropriate first-line medical therapy to manage chronic constipation. Stimulant laxatives, such as bisacodyl, can be considered for rescue therapy or as a second-line therapy, if needed.
- Colonic motility and transit should be measured before surgical intervention is considered.
- Biofeedback therapy is considered a first-line treatment for patients with symptomatic pelvic floor dyssynergia.
- Stapled trans-anal rectal resection (STARR) is not recommended for the repair of rectocele or internal rectal intussusception due to the high complication rates associated with this procedure.
Conditional recommendations
The guidelines also include 7 conditional recommendations:
- Objective measures assessing the nature and severity can be useful when evaluating patients with constipation.
- Patients who fail to improve with dietary changes, fiber therapy, and osmotic laxatives should be evaluated for outlet dysfunction. Anorectal physiology testing or dynamic imaging by fluoroscopic defecography, MRI defecography, or dynamic ultrasound may help identify functional or structural etiologies related to an evacuation disorder.
- Injecting botulinum toxin into the puborectalis and external sphincter muscle may be considered in patients with outlet dysfunction constipation related to nonrelaxing puborectalis muscle.
- Patients with significant outlet dysfunction from a rectocele may be considered for surgical repair after addressing any concomitant functional etiologies such as nonrelaxing puborectalis muscle.
- Repair of rectal intussusception may be considered in patients with severe obstructed defecation in whom nonoperative treatments were unsuccessful.
- Patients with isolated refractory colonic slow-transit constipation may benefit from total abdominal colectomy with ileorectal anastomosis.
- Fecal diversion may be considered in patients with intractable constipation refractory to other treatment options.
"Given the range of specialties that manage constipation, a collaborative approach is often warranted to achieve optimal patient outcomes," the guidelines committee emphasizes.
Wolters Kluwer provides trusted clinical technology and evidence-based solutions that engage clinicians, patients, researchers and students in effective decision-making and outcomes across healthcare. We support clinical effectiveness, learning and research, clinical surveillance and compliance, as well as data solutions. For more information about our solutions, visit .
###
About Wolters Kluwer
Wolters Kluwer (EURONEXT: WKL) is a global leader in information, software, and services for professionals in healthcare, tax and accounting, financial and corporate compliance, legal and regulatory, and corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2023 annual revenues of €5.6 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,400 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.
For more information, visit and follow us on , , and .